Objectives: To elucidate the association between genetic polymorphisms of
CYP2A6 and
CYP2E1 and urothelial cancer susceptibility.
Methods: A total of 137 Japanese patients with urothelial cancer and 217 Japanese healthy controls, frequency-matched for age and gender, were selected. The polymorphisms of
CYP2A6 and
CYP2E1 were analyzed by PCR-RFLP, and cigarette smoking histories were obtained through interviews.
Results: The frequency of
CYP2A6 homozygote deletion genotype was 2.9% in the patients, compared with 3.2% in the controls (OR=0.84, 95% CI 0.24−2.96). The frequencies of
CYP2E1 C1/c2 and
C2/c2 were 27.7% and 4.4% in the patients, compared with 35.5% and 6.0% in the controls (OR=0.68, 95% CI 0.42 −1.09, OR=0.67, 95% CI 0.24−1.84, respectively). No statistically significant differences were observed when the
CYP2A6 homozygote deletion genotype and the
CYP2E1 genotypes were examined relative to smoking status.
Conclusions: Our data indicate that neither a relationship between genetically impaired nitrosamine metabolism and tobacco-smoking consumption, nor urothelial cancer risk related to the
CYP2A6 deletion genotype and
CYP2E1 Rsa I genotype was found in Japanese population.
View full abstract